Biotech | August 17, 2022
Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology
Collaboration supports multiple discovery efforts, including vaccines
Collaboration supports multiple discovery efforts, including vaccines
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Company appoints five new independent directors to reconstituted board
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
New deal strengthens Congenica’s presence in India
Investment in response to increased demand for North American-based chemistry services
Subscribe To Our Newsletter & Stay Updated
